Bio

Dr. Alex Rodriguez is a Clinical Assistant Professor in the Multi-Specialty Division of the Stanford Department of Anesthesiology, Perioperative, and Pain Medicine. He completed his undergraduate studies at the University of Wisconsin-Madison, graduating with a double major in Neurobiology and Psychology and earning Honors in the Liberal Arts. He then attended the Northwestern University Feinberg School of Medicine, where he graduated summa cum laude and received multiple accolades, including the prestigious American Medical Association Physicians of Tomorrow Award and induction into the Alpha Omega Alpha honor society.

Dr. Rodriguez pursued residency training at Stanford University in the combined Internal Medicine and Anesthesiology program, distinguishing himself as an Outstanding Resident of the Year. He is board-certified in Internal Medicine and board-eligible in Anesthesiology, showcasing his dedication to multidisciplinary expertise.

At Stanford, Dr. Rodriguez plays an active role in medical education, serving as an oral board examiner for the Anesthesiology Residency Program and contributing as an author to the Stanford CA1 Tutorial Textbook. His clinical interests include critical care, cardiothoracic anesthesiology, point-of-care ultrasound, advanced airway management, and perioperative medicine. Within the Multi-Specialty Division, he has developed specialized expertise in abdominal and hepatobiliary surgery and is a member of the "High-Risk" team, who cares for patients with severe illness undergoing non-cardiac surgery.

In addition to his clinical work, Dr. Rodriguez is a member of the Departmental Quality Council, where he focuses on quality improvement and patient safety initiatives. His contributions underscore his commitment to advancing standards of care and enhancing patient outcomes.

Clinical Focus

  • Anesthesia

Academic Appointments

Professional Education

  • Residency: Stanford University Anesthesiology Residency (2024) CA
  • Medical Education: Northwestern University Feinberg School of Medicine (2019) IL

Contact

  • Academic
    ajrod@stanford.edu
    University - Academic staff Department: Anesthesia - MSD Position: Clinical Assistant Professor
  • Clinical (Primary)  Medicine 300 Pasteur Dr Rm JC007 Stanford, CA 94305 (650) 725-8381 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5640

All Publications

  • Intraoperative Seizure Under General Anesthesia Not Detected by EEG: A Case Report CUREUS JOURNAL OF MEDICAL SCIENCE Kumar, S., Rodriguez, A. J., Burbridge, M. A. 2023; 15 (7)

    View details for DOI 10.7759/cureus.42765

    View details for Web of Science ID 001046815900023

  • Intraoperative Seizure Under General Anesthesia Not Detected by EEG: A Case Report. Cureus Kumar, S., Rodriguez, A. J., Burbridge, M. A. 2023; 15 (7): e42765

    Abstract

    Intraoperative seizures under general anesthesia are infrequent. However, seizure activity under general anesthesia confirmed by contemporaneous EEG has been reported. We describe the case of a 39-year-old female undergoing right frontal brain tumor resection who experienced an intraoperative seizure. Intraoperative neuromonitoring was utilized and included four channels of EEG, somatosensory evoked potentials (SSEP), and transcranial motor evoked potentials (MEP). During this operation, characteristic motor manifestations of a seizure occurred. However, the EEG did not demonstrate seizure activity due to limitations in EEG lead placement. Post-operatively in the ICU, motor manifestations of seizure activity continued, and subsequent EEG recordings demonstrated classic seizure activity. Due to the previous hemicraniectomy, corkscrew EEG electrodes were not placed over the right skull defect, thereby failing to detect the intraoperative seizure. Anesthesiologists should be aware that limitations with EEG electrode placement can fail to detect intraoperative seizures, and treatment to extinguish the seizure should proceed in an emergent fashion.

    View details for DOI 10.7759/cureus.42765

    View details for PubMedID 37663980

    View details for PubMedCentralID PMC10468727

  • The Use of Factor Eight Inhibitor Bypass Activity (FEIBA) for the Treatment of Perioperative Hemorrhage in Left Ventricular Assist Device Implantation. Journal of cardiothoracic and vascular anesthesia O'Donnell, C., Rodriguez, A. J., Madhok, J., Sharifi, H., Wang, H., O'Brien, C. G., Boyd, J., Hiesinger, W., Hsu, J., Hill, C. C. 2021

    Abstract

    OBJECTIVE: To test the hypothesis that factor eight inhibitor bypassing activity (FEIBA) can be used to control bleeding following left ventricular assist device (LVAD) implantation without increasing the 14-day composite thrombotic outcome of pump thrombus, ischemic cerebrovascular accidents, pulmonary embolism, and deep venous thrombosis.DESIGN: Retrospective cohort study.SETTING: Academic hospital.PARTICIPANTS: Three hundred nineteen consecutive patients who underwent LVAD implantation (December 1, 2009 to December 30, 2018).INTERVENTION: FEIBA administered to control perioperative hemorrhage.MEASUREMENTS AND MAIN RESULTS: The 82 patients (25.7%) in the FEIBA cohort had more risk factors for perioperative hemorrhage, such as lower preoperative platelet count (169 ± 66 v 194 ± 68 * 103/mL, p = 0.004), prior cardiac surgery (36.6% v 21.9%, p = 0.008), and longer cardiopulmonary bypass (CPB) time (100.3 v 75.2 minutes, p = 0.001) than the 237 controls. After 16.6 units (95% CI: 14.3-18.9) of blood products were given, 992 units (95% CI: 821-1163) of FEIBA were required to control bleeding in the FEIBA cohort. Compared to the controls, there were no differences in the 14-day composite thrombotic outcome (11.0% v 7.6%, p = 0.343) or mortality rate (3.7% v 1.3%, p = 0.179). Multivariate logistical regression identified preoperative international normalized ratio (odds ratio [OR]: 1.30, 95% CI: 1.04-1.62) and CPB time (OR: 1.11, 95% CI: 1.02-1.20) as risk factors for 14-day thrombotic events, but FEIBA usage was not associated with an increased risk.CONCLUSIONS: In this retrospective cohort study, the use of FEIBA (1,000 units, 13 units/kg) to control perioperative hemorrhage following LVAD implantation was not associated with increases in mortality or composite thrombotic outcome.

    View details for DOI 10.1053/j.jvca.2021.04.030

    View details for PubMedID 34034934

  • THE SAFETY AND EFFICACY OF PERIOPERATIVE FEIBA AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION ODonnell, C., Rodriguez, A., Madhok, J., Wang, H., Shad, R., Sharifi, H., Boyd, J., William, H., Hsu, J., Hill, C. LIPPINCOTT WILLIAMS & WILKINS. 2021: 168

    View details for Web of Science ID 000672597100323